Showing results (11-20 of 229) with videos related to
Sort By:
Pageof 23
Med (New York, N.Y.)|October 11, 2025
Targeting the glucocorticoid receptor as a therapeutic strategy for ovarian cancer: The ROSELLA studyTaliya Lantsman, Ursula A MatulonisFrontiers in Oncology|December 31, 2013
Current status and evolution of preclinical drug development models of epithelial ovarian cancerPanagiotis A Konstantinopoulos, Ursula A MatulonisNature Cancer|August 31, 2023
Clinical and translational advances in ovarian cancer therapyPanagiotis A Konstantinopoulos, Ursula A MatulonisHematology/Oncology Clinics of North America|November 5, 2018
Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian CancerPanagiotis A Konstantinopoulos, Ursula A MatulonisCurrent Oncology Reports|March 18, 2016
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?Joyce F Liu, Ursula A MatulonisExpert Review of Anticancer Therapy|July 17, 2023
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancerRebecca L Porter, Ursula A MatulonisClinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2018
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative JourneyPanagiotis A Konstantinopoulos, Ursula A MatulonisCancers|July 30, 2020
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination TherapiesElizabeth K Lee, Ursula A MatulonisExpert Opinion on Emerging Drugs|June 23, 2020
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitorsElizabeth K Lee, Ursula A MatulonisJournal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Chemotherapy hypersensitivity reactions in ovarian cancerMatthieu Picard, Ursula A Matulonis, Mariana CastellsPageof 23